Esperion Therapeutics filings document the regulatory record of a commercial-stage biopharmaceutical company focused on LDL-C lowering, cardiovascular-risk therapies, and related cardiometabolic programs. Its Form 8-K reports cover operating and financial results, clinical or regulatory disclosures, material agreements, capital-structure matters, and material-event updates tied to its commercial portfolio and development activities.
Esperion's SEC record also includes proxy disclosures on shareholder voting, board governance, executive compensation, equity awards, and pay-versus-performance information. Recent filings describe common stock registered on Nasdaq under ESPR, term-loan and credit-agreement amendments, acquisition-related financing, commercial leadership appointments, and other governance and compensation arrangements.
Esperion Therapeutics, Inc. filed an 8-K reporting a material event that centers on a securities offering. The filing references two press releases dated October 7, 2025: one announcing the offering and one announcing the pricing of the offering. The company also disclosed an opinion of Goodwin Procter LLP and the firm's consent (included as Exhibit 5.1). The document includes the interactive data cover page and is signed by Sheldon Koenig, President and Chief Executive Officer on October 8, 2025. The filing shows the offering has been publicly announced and legally documented, but it does not disclose offering size, securities type, or net proceeds.
Esperion Therapeutics, Inc. is offering 30,000,000 shares of common stock at a public offering price of $2.50 per share, with an underwriter option for an additional 4,500,000 shares. Estimated net proceeds are approximately $70.2M (or $80.7M if option exercised). The company plans to use proceeds to fund commercialization of NEXLETOL and NEXLIZET, R&D, working capital and general corporate purposes. Recent corporate developments include a settlement with Dr. Reddy’s that delays generic entry for NEXLETOL and NEXLIZET in the U.S. until April 19, 2040, and regulatory progress with approvals and filings in Japan, Canada, Israel and Australia with expected national pricing/approvals in late 2025 to 2026. The offering will dilute new investors; pro forma net tangible book value remains negative at $(1.56) per share after the offering, producing an immediate dilution of $4.06 per share to new investors.
Esperion Therapeutics, Inc. is offering additional shares of its common stock on a shelf registration, with the final public offering price to be set at pricing. The company reported a closing Nasdaq price of $3.30 per share on October 3, 2025 and had 202,149,464 shares outstanding as of June 30, 2025. The prospectus details intended uses of proceeds for commercialization of NEXLETOL and NEXLIZET, pipeline development, working capital and general corporate purposes. Recent corporate developments include a settlement with Dr. Reddy’s delaying generic entry in the U.S. until April 19, 2040 under specified conditions. The company reported a pro forma net tangible book deficit of approximately $(433.5) million (about $(2.14) per share) as of June 30, 2025, and discloses material dilution and volatility risks for investors.
Esperion Therapeutics, Inc. is offering additional shares of its common stock on a shelf registration, with the final public offering price to be set at pricing. The company reported a closing Nasdaq price of $3.30 per share on October 3, 2025 and had 202,149,464 shares outstanding as of June 30, 2025. The prospectus details intended uses of proceeds for commercialization of NEXLETOL and NEXLIZET, pipeline development, working capital and general corporate purposes. Recent corporate developments include a settlement with Dr. Reddy’s delaying generic entry in the U.S. until April 19, 2040 under specified conditions. The company reported a pro forma net tangible book deficit of approximately $(433.5) million (about $(2.14) per share) as of June 30, 2025, and discloses material dilution and volatility risks for investors.
Esperion Therapeutics, Inc. filed a current report to note that on October 7, 2025 it posted an updated corporate presentation on its investor relations website. The same presentation, dated October 2025, is also provided as Exhibit 99.1 so investors can review the materials directly through the SEC system.
The filing does not introduce new financial statements or disclose specific transaction details. Instead, it formally records that the latest corporate overview and investor slide deck are now publicly available, helping ensure all market participants have equal access to the company’s updated messaging.
Esperion Therapeutics, Inc. filed a current report to note that on October 7, 2025 it posted an updated corporate presentation on its investor relations website. The same presentation, dated October 2025, is also provided as Exhibit 99.1 so investors can review the materials directly through the SEC system.
The filing does not introduce new financial statements or disclose specific transaction details. Instead, it formally records that the latest corporate overview and investor slide deck are now publicly available, helping ensure all market participants have equal access to the company’s updated messaging.
Esperion Therapeutics insider transaction: Benjamin Looker, listed as General Counsel and an officer, reported a sale of 6,267 shares of Esperion Therapeutics common stock on 09/17/2025 at a reported price of $2.804 per share. The filing states the shares were sold to satisfy tax obligations on vested restricted stock units. After the sale, Mr. Looker is reported to beneficially own 393,670 shares, held directly. The Form 4 was signed by a power of attorney on 09/18/2025. The report contains no other derivative transactions or additional explanatory disclosures.
Esperion Therapeutics insider transaction: Benjamin Looker, listed as General Counsel and an officer, reported a sale of 6,267 shares of Esperion Therapeutics common stock on 09/17/2025 at a reported price of $2.804 per share. The filing states the shares were sold to satisfy tax obligations on vested restricted stock units. After the sale, Mr. Looker is reported to beneficially own 393,670 shares, held directly. The Form 4 was signed by a power of attorney on 09/18/2025. The report contains no other derivative transactions or additional explanatory disclosures.
Sheldon L. Koenig, President and CEO and Director of Esperion Therapeutics (ESPR), reported a sale and updated holdings. On 09/17/2025 he disposed of 28,427 shares of Esperion common stock at $2.788 per share to satisfy tax obligations on vested restricted stock units. After the reported disposition and recent ESPP purchases, Koenig beneficially owns 1,518,831 shares, which includes 5,770 shares acquired through the company's Employee Stock Purchase Plan. The Form 4 filing is signed 09/18/2025 and reflects that the reporting person is both an officer and a director.
Sheldon L. Koenig, President and CEO and Director of Esperion Therapeutics (ESPR), reported a sale and updated holdings. On 09/17/2025 he disposed of 28,427 shares of Esperion common stock at $2.788 per share to satisfy tax obligations on vested restricted stock units. After the reported disposition and recent ESPP purchases, Koenig beneficially owns 1,518,831 shares, which includes 5,770 shares acquired through the company's Employee Stock Purchase Plan. The Form 4 filing is signed 09/18/2025 and reflects that the reporting person is both an officer and a director.
Esperion Therapeutics CFO Benjamin Halladay reported a sale and recent employee-plan purchase on Form 4. On 09/17/2025 he disposed of 7,046 shares of Esperion common stock at a price of $2.808 per share to satisfy tax obligations tied to vested restricted stock units. Following the reported transactions, Mr. Halladay beneficially owns 474,862 shares, which the filing notes includes 7,446 shares recently acquired through Esperion's Employee Stock Purchase Plan. The filing was signed by power of attorney on 09/18/2025.
Esperion Therapeutics CFO Benjamin Halladay reported a sale and recent employee-plan purchase on Form 4. On 09/17/2025 he disposed of 7,046 shares of Esperion common stock at a price of $2.808 per share to satisfy tax obligations tied to vested restricted stock units. Following the reported transactions, Mr. Halladay beneficially owns 474,862 shares, which the filing notes includes 7,446 shares recently acquired through Esperion's Employee Stock Purchase Plan. The filing was signed by power of attorney on 09/18/2025.
Esperion Therapeutics (ESPR) report of proposed sale under Rule 144: An individual plans to sell 28,427 common shares through Fidelity Brokerage Services on 09/17/2025, with an aggregate market value of $79,240.27. The shares were acquired on 09/15/2025 via restricted stock vesting and payment was for compensation. The filing lists 201,622,825 shares outstanding, so the proposed sale represents a very small fraction of total shares. The filer also reported a prior sale of 30,474 shares on 06/17/2025 generating $33,792.63. The filing includes the seller's representation regarding material nonpublic information.
Form 144 filed for ESPR insider Benjamin Halladay proposes to sell 7,046 shares of common stock on or about 09/17/2025. The shares were acquired on 09/15/2025 upon restricted stock vesting and are being sold as compensation. The filing lists an aggregate market value of $19,788.69 for the proposed sale versus 201,622,825 shares outstanding, indicating the sale is a very small fraction of the company. The filer previously sold 7,229 shares on 06/17/2025 for $8,329.25 and 11 shares on 07/17/2025 for $12.27. The signer certifies no undisclosed material adverse information.
Esperion Therapeutics (ESPR) Form 144 notice: The filer reports a proposed sale of 6,267 common shares with an aggregate market value of $17,575.80, to be sold through Fidelity Brokerage Services LLC on or about 09/17/2025 on the NASDAQ. The shares were acquired on 09/15/2025 by restricted stock vesting from the issuer and were paid as compensation. The filing also discloses sales by the same person in the prior three months: 6,422 shares sold on 06/17/2025 for $7,397.50 and 1,304 shares sold on 07/17/2025 for $1,469.35. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information.